{"id":"W2903241832","doi":"10.1016/j.eururo.2018.11.033","title":"Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Mitoxantrone; Cabozantinib; Prostate cancer; Clinical endpoint; Prednisone; Enzalutamide; Oncology; Randomized controlled trial; Internal medicine; Cancer; Anesthesia; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002522571,0.0003049091,0.0009585042,0.0002803045,0.0001115755,0.00003845332,0.0001382527,0.00004062242,0.0002760426],"category_scores_gemma":[0.0004952807,0.0002027136,0.0001201732,0.0003519559,0.0007065944,0.00008844429,0.0000557205,0.00029279,0.00007508235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001496458,"about_ca_system_score_gemma":0.0006120424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001633777,"about_ca_topic_score_gemma":0.0002770796,"domain_scores_codex":[0.9953036,0.002501067,0.0006710032,0.000521491,0.0003666197,0.0006362392],"domain_scores_gemma":[0.9982566,0.0007821307,0.0002313968,0.0003828249,0.0001469002,0.0002000948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840527,0.0008340876,0.0001434507,0.0001270508,0.000595421,0.001801385,0.001621,0.000006897294,0.004323152,0.00005708259,0.0004211481,0.00601667],"study_design_scores_gemma":[0.978439,0.0155829,0.0009045389,0.0000995421,0.0005595208,0.00004179314,0.0001584659,0.0008930241,0.0004885916,0.00002247025,0.002591664,0.0002185315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853759,0.001520944,0.0002190232,0.002871528,0.000358573,0.00424635,0.00005911072,0.00009867927,0.005249905],"genre_scores_gemma":[0.9964858,0.0002952974,0.0008123374,0.0004907088,0.0003892766,0.0004344485,0.0001620944,0.00007173303,0.0008582495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01474882,"threshold_uncertainty_score":0.826642,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0304704911735106,"score_gpt":0.3315535634413619,"score_spread":0.3010830722678513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}